Publication

Imaging cardiac innervation in amyloidosis

Slart, R. H. J. A., Glaudemans, A. W. J. M., Hazenberg, B. P. C. & Noordzij, W., 2019, In : Journal of Nuclear Cardiology. 26, p. 174-187 14 p.

Research output: Contribution to journalArticleAcademicpeer-review

Cardiac amyloidosis is a form of restrictive cardiomyopathy resulting in heart failure and potential risk on arrhythmia, due to amyloid infiltration of the nerve conduction system and the myocardial tissue. The prognosis in this progressive disease is poor, probably due the development of cardiac arrhythmias. Early detection of cardiac sympathetic innervation disturbances has become of major clinical interest, because its occurrence and severity limits the choice of treatment. The use of iodine-123 labelled metaiodobenzylguanidine ([I-123]MIBG), a chemical modified analogue of norepinephrine, is well established in patients with heart failure and plays an important role in evaluation of sympathetic innervation in cardiac amyloidosis. [I-123]MIBG is stored in vesicles in the sympathetic nerve terminals and is not catabolized like norepinephrine. Decreased heart-to-mediastinum ratios on late planar images and increased wash-out rates indicate cardiac sympathetic denervation and are associated with poor prognosis. Single photon emission computed tomography provides additional information and has advantages for evaluating abnormalities in regional distribution in the myocardium. [I-123]MIBG is mainly useful in patients with hereditary and wild-type ATTR cardiac amyloidosis, not in AA and AL amyloidosis. The potential role of positron emission tomography for cardiac sympathetic innervation in amyloidosis has not yet been identified.

Original languageEnglish
Pages (from-to)174-187
Number of pages14
JournalJournal of Nuclear Cardiology
Volume26
Publication statusPublished - 2019

    Keywords

  • Journal Article

View graph of relations

Download statistics

No data available

ID: 47808831